Pub Date : 2019-10-02DOI: 10.1080/24750573.2018.1454374
N. Bolat, K. Eliaçık, M. Yavuz, A. Kanık, Hilal Mertek, B. Guven, B. Dogrusoz, A. R. Bakiler
ABSTRACT OBJECTIVES: Psychological factors may be the underlying causes in unexplained chest pain (UCP). Chest pain symptom may influence the emotional status and peer relationships of the children and adolescents negatively. However, the number of studies focussing on the aetiology and consequences of the adolescent UCP are still limited. The aim of this study is to investigate the relationships among psychological problems, attachment characteristics, and the UCP in a group of adolescents. METHODS: Seventy-three adolescents with UCP and seventy-one healthy adolescents were included in the study. The adolescents completed the short form of Inventory of Parent and Peer Attachment (s-IPPA), and Strengths and Difficulties Questionnaire (SDQ), while their parents completed the parental form of the SDQ. RESULTS: Contrary to expectations, there was no significant interaction between total parental attachment levels and UCP in the adolescents with UCP. There were significant correlations between the attachment problems and total difficulties score of SDQ. Binary logistic regression analysis revealed that higher emotional and conduct problems and lower pro-social characteristics predict the UCP in adolescents, significantly. CONCLUSIONS: The results suggested that emotional/behavioural problems and lower pro-social behaviour scores are associated with UCP. However, further studies are needed for better understanding about the relationships between the UCP and attachment quality.
{"title":"Adolescent mental health, attachment characteristics, and unexplained chest pain: a case–control study","authors":"N. Bolat, K. Eliaçık, M. Yavuz, A. Kanık, Hilal Mertek, B. Guven, B. Dogrusoz, A. R. Bakiler","doi":"10.1080/24750573.2018.1454374","DOIUrl":"https://doi.org/10.1080/24750573.2018.1454374","url":null,"abstract":"ABSTRACT OBJECTIVES: Psychological factors may be the underlying causes in unexplained chest pain (UCP). Chest pain symptom may influence the emotional status and peer relationships of the children and adolescents negatively. However, the number of studies focussing on the aetiology and consequences of the adolescent UCP are still limited. The aim of this study is to investigate the relationships among psychological problems, attachment characteristics, and the UCP in a group of adolescents. METHODS: Seventy-three adolescents with UCP and seventy-one healthy adolescents were included in the study. The adolescents completed the short form of Inventory of Parent and Peer Attachment (s-IPPA), and Strengths and Difficulties Questionnaire (SDQ), while their parents completed the parental form of the SDQ. RESULTS: Contrary to expectations, there was no significant interaction between total parental attachment levels and UCP in the adolescents with UCP. There were significant correlations between the attachment problems and total difficulties score of SDQ. Binary logistic regression analysis revealed that higher emotional and conduct problems and lower pro-social characteristics predict the UCP in adolescents, significantly. CONCLUSIONS: The results suggested that emotional/behavioural problems and lower pro-social behaviour scores are associated with UCP. However, further studies are needed for better understanding about the relationships between the UCP and attachment quality.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"52 1","pages":"487 - 491"},"PeriodicalIF":0.7,"publicationDate":"2019-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86838560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-02DOI: 10.1080/24750573.2018.1470215
Lütfiye Söğütlü, N. Alaca, L. Önen
ABSTRACT PURPOSE: This study was planned to assess the attention and memory-based performances of workers who used solvent as part of their job and therefore who had been exposed to this substance for a long time. METHOD: The participants of the study are 31 workers who were diagnosed with solvent exposure in the occupational diseases polyclinic of Istanbul Occupational Diseases Hospital and who were treated as inpatient treatment. These 31 participants were individuals who worked for at least 1 year in solvent use, and who did not have any physical, neurological, or psychiatric diseases prior to the study. Beside the aforementioned study group, 30 healthy volunteers also participated in the study as the control group. The verbal memory processes test (VMPT), cancellation test (CT) and Stroop test TBAG form (STP) were applied to all participants. FINDINGS: The data revealed no significant difference between the study and control groups in terms of their short-term memory scores based on the VMPT scores of the participants. However, long-term memory scores, learning achievement scores and the highest learning achievement scores of the study group were found to be significantly lower than the control group. Comparing the two groups on CT and its sub-sections, the scores of the study group were found to be significantly higher than the control group. These findings present that the study group needed more time to complete the mentioned test. It was also revealed that the study group particularly completed the fifth sub-section of STP, which focuses on selective attention, in significantly longer amount of time than the control group. CONCLUSION: Long-term solvent exposure affects attention and memory processes negatively.
{"title":"Examination of attention and memory processes of workers exposed to solvent for a long time","authors":"Lütfiye Söğütlü, N. Alaca, L. Önen","doi":"10.1080/24750573.2018.1470215","DOIUrl":"https://doi.org/10.1080/24750573.2018.1470215","url":null,"abstract":"ABSTRACT PURPOSE: This study was planned to assess the attention and memory-based performances of workers who used solvent as part of their job and therefore who had been exposed to this substance for a long time. METHOD: The participants of the study are 31 workers who were diagnosed with solvent exposure in the occupational diseases polyclinic of Istanbul Occupational Diseases Hospital and who were treated as inpatient treatment. These 31 participants were individuals who worked for at least 1 year in solvent use, and who did not have any physical, neurological, or psychiatric diseases prior to the study. Beside the aforementioned study group, 30 healthy volunteers also participated in the study as the control group. The verbal memory processes test (VMPT), cancellation test (CT) and Stroop test TBAG form (STP) were applied to all participants. FINDINGS: The data revealed no significant difference between the study and control groups in terms of their short-term memory scores based on the VMPT scores of the participants. However, long-term memory scores, learning achievement scores and the highest learning achievement scores of the study group were found to be significantly lower than the control group. Comparing the two groups on CT and its sub-sections, the scores of the study group were found to be significantly higher than the control group. These findings present that the study group needed more time to complete the mentioned test. It was also revealed that the study group particularly completed the fifth sub-section of STP, which focuses on selective attention, in significantly longer amount of time than the control group. CONCLUSION: Long-term solvent exposure affects attention and memory processes negatively.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"20 3","pages":"533 - 537"},"PeriodicalIF":0.7,"publicationDate":"2019-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/24750573.2018.1470215","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72369826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-02DOI: 10.1080/24750573.2019.1699726
J. Ye, Xiaodong Lin, Deguo Jiang, Min Chen, Yanchi Zhang, H. Tian, Jie Li, C. Zhuo, Yanling Zhao
ABSTRACT BACKGROUND: To investigate the effects of adjunct ketamine treatment on depressive symptoms and brain activity in chronic treatment-resistant schizophrenia (CTRS) patients with treatment-resistant depressive (TRD) symptoms. METHODS: Calgary Depression Scale for Schizophrenia (CDSS), positive and negative syndrome scale (PANSS), and regional homogeneity (ReHo) results were compared before versus after ketamine treatment in 12 CTRS patients with TRD symptoms. RESULTS: From 7 days to 14 days after the first ketamine administration, CDSS and PANSS total scores were reduced by 63.8% and 12.9%, respectively. By day 21, ReHo values had increased in the main components of the default mode network (DMN) and bilateral orbitofrontal cortex (OFC) after family-wise error correction. ReHo alterations did not correlate with TRD symptom changes. TRD symptoms relapsed by the 21-day time point, while increased ReHo was sustained. No adverse secondary effects (ASEs) necessitating medical intervention occurred. CONCLUSIONS: Adjunct ketamine alleviation of TRD symptoms lasted only a week, whereas increased ReHo in DMN regions and the OFC in CTRS patients was maintained beyond 2 weeks, indicating that adjunct ketamine is not well-suited for CTRS patients with TRD symptoms and that effects on functional activity dissociate from effects on TRD symptoms. This small-sample pilot study provides clues for further research into therapy for TRD symptoms in CTRS patients.
{"title":"Adjunct ketamine treatment effects on treatment-resistant depressive symptoms in chronic treatment-resistant schizophrenia patients are short-term and disassociated from regional homogeneity changes in key brain regions – a pilot study","authors":"J. Ye, Xiaodong Lin, Deguo Jiang, Min Chen, Yanchi Zhang, H. Tian, Jie Li, C. Zhuo, Yanling Zhao","doi":"10.1080/24750573.2019.1699726","DOIUrl":"https://doi.org/10.1080/24750573.2019.1699726","url":null,"abstract":"ABSTRACT BACKGROUND: To investigate the effects of adjunct ketamine treatment on depressive symptoms and brain activity in chronic treatment-resistant schizophrenia (CTRS) patients with treatment-resistant depressive (TRD) symptoms. METHODS: Calgary Depression Scale for Schizophrenia (CDSS), positive and negative syndrome scale (PANSS), and regional homogeneity (ReHo) results were compared before versus after ketamine treatment in 12 CTRS patients with TRD symptoms. RESULTS: From 7 days to 14 days after the first ketamine administration, CDSS and PANSS total scores were reduced by 63.8% and 12.9%, respectively. By day 21, ReHo values had increased in the main components of the default mode network (DMN) and bilateral orbitofrontal cortex (OFC) after family-wise error correction. ReHo alterations did not correlate with TRD symptom changes. TRD symptoms relapsed by the 21-day time point, while increased ReHo was sustained. No adverse secondary effects (ASEs) necessitating medical intervention occurred. CONCLUSIONS: Adjunct ketamine alleviation of TRD symptoms lasted only a week, whereas increased ReHo in DMN regions and the OFC in CTRS patients was maintained beyond 2 weeks, indicating that adjunct ketamine is not well-suited for CTRS patients with TRD symptoms and that effects on functional activity dissociate from effects on TRD symptoms. This small-sample pilot study provides clues for further research into therapy for TRD symptoms in CTRS patients.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"58 1","pages":"907 - 915"},"PeriodicalIF":0.7,"publicationDate":"2019-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84446590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-02DOI: 10.1080/24750573.2018.1459005
D. Unal, Fahri Çelebi, Hacer Neslihan Bildik, A. Koyuncu, S. Karahan
ABSTRACT OBJECTIVE: In this study, we evaluated vitamin B12 and iron parameters in Turkish children with ADHD in order to examine the relationship between ADHD symptoms and these parameters. METHODS: Drug-naive 100 ADHD patients, aged between 6 and 12 years old, were included in the study. None of them had acute or chronic diseases. All patients were assessed by using the Schedule for Affective Disorders and Schizophrenia for School Age Children – Present and Lifetime Version (K-SADS-PL). Conners Parent Rating Scale (CPRS) was used for screening ADHD symptoms and symptom severity. Blood samples were evaluated for ferritin, haemoglobin, MCV, RDW, and vitamin B12 parameters. RESULTS: We indicated an inverse relationship between haemoglobin levels and learning, anxiety subscale scores of CPRS. Also, vitamin B12 and psychosomatic subscale scores were found negatively related whereas the relationship was in the opposite direction for ferritin. Vitamin B12 level was negatively correlated with learning problems and psychosomatic subscales of CTRS in the combined subtype of ADHD. CONCLUSION: Vitamin B12 and iron support may be useful in treatment of childhood ADHD, especially for learning problems, besides medication.
{"title":"Vitamin B12 and haemoglobin levels may be related with ADHD symptoms: a study in Turkish children with ADHD","authors":"D. Unal, Fahri Çelebi, Hacer Neslihan Bildik, A. Koyuncu, S. Karahan","doi":"10.1080/24750573.2018.1459005","DOIUrl":"https://doi.org/10.1080/24750573.2018.1459005","url":null,"abstract":"ABSTRACT OBJECTIVE: In this study, we evaluated vitamin B12 and iron parameters in Turkish children with ADHD in order to examine the relationship between ADHD symptoms and these parameters. METHODS: Drug-naive 100 ADHD patients, aged between 6 and 12 years old, were included in the study. None of them had acute or chronic diseases. All patients were assessed by using the Schedule for Affective Disorders and Schizophrenia for School Age Children – Present and Lifetime Version (K-SADS-PL). Conners Parent Rating Scale (CPRS) was used for screening ADHD symptoms and symptom severity. Blood samples were evaluated for ferritin, haemoglobin, MCV, RDW, and vitamin B12 parameters. RESULTS: We indicated an inverse relationship between haemoglobin levels and learning, anxiety subscale scores of CPRS. Also, vitamin B12 and psychosomatic subscale scores were found negatively related whereas the relationship was in the opposite direction for ferritin. Vitamin B12 level was negatively correlated with learning problems and psychosomatic subscales of CTRS in the combined subtype of ADHD. CONCLUSION: Vitamin B12 and iron support may be useful in treatment of childhood ADHD, especially for learning problems, besides medication.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"129 1","pages":"515 - 519"},"PeriodicalIF":0.7,"publicationDate":"2019-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77457686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-27DOI: 10.1080/24750573.2019.1662629
Jianjie Huang, Min Chen, Ce Chen, Xiaodong Lin, Deguo Jiang, Yonghui Zhang, Lina Wang, C. Zhuo, H. Tian, C. Du
ABSTRACT Background: The present study aimed to systematically evaluate three prolactin-sparing antipsychotics for treating schizophrenia. Methods: We performed a meta-analysis of three prolactin-sparing antipsychotics in patients with schizophrenia. Endpoints of interest were the Positive and Negative Syndrome Scale (PANSS), Brief Psychiatric Rating Scale (BPRS), Clinical Global Impressions-Severity (CGI-S) and acceptability (all cause discontinuation). Results: A total of 12 trials (2,723 patients) and three drugs (aripiprazole, quetiapine, and ziprasidone) were included. On the PANSS scale, aripiprazole (mean difference [MD]: −6.98, 95% CrI: −12.35, −1.38) was statistically more effective than placebo. When assessed by BPRS, aripiprazole (MD: −9.01, 95% CrI: −15.81, −3.12), quetiapine (MD: −7.13, 95% CrI: −9.78, −4.29) and ziprasidone (MD: −4.97, 95% CrI: 9.96, −0.21) had greater efficacy, when compared to placebo. Regarding CGI-S, quetiapine (MD: −0.55, 95% CrI: −0.82, −0.25) was significantly superior to placebo. In terms of acceptability, aripiprazole (OR: 0.54, 95% CrI: 0.41, 0.73), quetiapine (OR: 0.49, 95% CrI: 0.36, 0.68) and ziprasidone (OR: 0.68, 95% CrI: 0.48, 0.96) were more acceptable than placebo. The benefit risk analysis revealed that quetiapine has the best efficacy and acceptability profile among the three prolactin-sparing antipsychotics. Conclusions: Quetiapine may offer an optimal benefit-risk balance when a prolactin-sparing antipsychotic is indicated.
{"title":"Efficacy and acceptability of three prolactin-sparing antipsychotics in patient with schizophrenia: a network meta-analysis","authors":"Jianjie Huang, Min Chen, Ce Chen, Xiaodong Lin, Deguo Jiang, Yonghui Zhang, Lina Wang, C. Zhuo, H. Tian, C. Du","doi":"10.1080/24750573.2019.1662629","DOIUrl":"https://doi.org/10.1080/24750573.2019.1662629","url":null,"abstract":"ABSTRACT Background: The present study aimed to systematically evaluate three prolactin-sparing antipsychotics for treating schizophrenia. Methods: We performed a meta-analysis of three prolactin-sparing antipsychotics in patients with schizophrenia. Endpoints of interest were the Positive and Negative Syndrome Scale (PANSS), Brief Psychiatric Rating Scale (BPRS), Clinical Global Impressions-Severity (CGI-S) and acceptability (all cause discontinuation). Results: A total of 12 trials (2,723 patients) and three drugs (aripiprazole, quetiapine, and ziprasidone) were included. On the PANSS scale, aripiprazole (mean difference [MD]: −6.98, 95% CrI: −12.35, −1.38) was statistically more effective than placebo. When assessed by BPRS, aripiprazole (MD: −9.01, 95% CrI: −15.81, −3.12), quetiapine (MD: −7.13, 95% CrI: −9.78, −4.29) and ziprasidone (MD: −4.97, 95% CrI: 9.96, −0.21) had greater efficacy, when compared to placebo. Regarding CGI-S, quetiapine (MD: −0.55, 95% CrI: −0.82, −0.25) was significantly superior to placebo. In terms of acceptability, aripiprazole (OR: 0.54, 95% CrI: 0.41, 0.73), quetiapine (OR: 0.49, 95% CrI: 0.36, 0.68) and ziprasidone (OR: 0.68, 95% CrI: 0.48, 0.96) were more acceptable than placebo. The benefit risk analysis revealed that quetiapine has the best efficacy and acceptability profile among the three prolactin-sparing antipsychotics. Conclusions: Quetiapine may offer an optimal benefit-risk balance when a prolactin-sparing antipsychotic is indicated.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"84 1","pages":"369 - 378"},"PeriodicalIF":0.7,"publicationDate":"2019-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74091524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-13DOI: 10.1080/24750573.2019.1663582
H. Karatepe, K. F. Yavuz
ABSTRACT OBJECTIVES: Mindfulness is the awareness that emerges through paying attention on purpose, in the present moment, and nonjudgementally to the unfolding of experience moment to moment. Mindfulness-based interventions are frequently used in clinical situations and in establishing psychological well-being in a non-clinical sample as psychological techniques. Therefore, many mindfulness measures have been developed for use in clinical settings and for research purposes. Freiburg Mindfulness Inventory (FMI) is a self-report questionnaire that was developed to measure the trait mindfulness. In this study, we aimed to examine the validity, reliability, and factor structure of the FMI in a Turkish sample. METHODS: Participants were mostly college students (113 female, 93 male) and civil servants. Sociodemographic information, the Turkish version of the FMI, Acceptance and Action Questionnaire-II (AAQ-II), Five Facets Mindfulness Questionnaire (FFMQ) – All statistical analyses were performed by using SPSS version 20 and AMOS 23 version. RESULTS: The Cronbach’s alpha coefficient for the scale was 0.823, Guttman’s split-half reliability coefficient was 0.828, and test–retest reliability coefficient was 0.895. A positive and statistically significant correlation was found between the Turkish FMI and FFMQ (r = 0.566, p = .000). We found negative and statistically significant results between FMI and AAQ-II scores (r = −0.519 p = .000). We found strong statistical fit indices that can be acceptable for one-factor solution confirmatory factor analysis. CONCLUSIONS: The Turkish version of the FMI has satisfactory convergent and divergent validity, good internal and test–retest reliability with one-factor structure to use in a Turkish sample. We hope that Turkish form of FMI, which is known to be effective in assessing the mindfulness especially in a population that is familiar with the mindfulness practices, will be a useful alternative instrument for Turkish clinicians and researchers.
目的:正念是一种意识，它通过有意识地、在当下时刻、不加判断地关注当下体验的展开而产生。以正念为基础的干预经常用于临床情况，并作为心理学技术在非临床样本中建立心理健康。因此，许多正念测量已被开发用于临床环境和研究目的。弗莱堡正念量表(FMI)是一种用于测量正念特质的自我报告问卷。在本研究中，我们旨在检验土耳其样本中FMI的效度、信度和因素结构。方法:调查对象主要为大学生(女113人，男93人)和公务员。社会人口统计信息，土耳其版FMI，接受和行动问卷- ii (AAQ-II)，五方面正念问卷(FFMQ) -所有统计分析均使用SPSS 20版和AMOS 23版进行。结果:量表的Cronbach 's alpha系数为0.823,Guttman 's split-half信度系数为0.828，重测信度系数为0.895。土耳其FMI与FFMQ呈正相关且有统计学意义(r = 0.566, p = .000)。我们发现FMI和AAQ-II评分之间呈负相关且有统计学意义(r = - 0.519 p = .000)。我们发现强统计拟合指标，可以接受的单因素解决验证性因素分析。结论:土耳其版FMI具有令人满意的收敛效度和发散效度，具有良好的内部信度和重测信度，单因素结构适用于土耳其样本。我们希望土耳其形式的FMI，已知在评估正念方面是有效的，特别是在熟悉正念练习的人群中，将成为土耳其临床医生和研究人员的有用替代工具。
{"title":"Reliability, validity, and factorial structure of the Turkish version of the Freiburg Mindfulness Inventory (Turkish FMI)","authors":"H. Karatepe, K. F. Yavuz","doi":"10.1080/24750573.2019.1663582","DOIUrl":"https://doi.org/10.1080/24750573.2019.1663582","url":null,"abstract":"ABSTRACT OBJECTIVES: Mindfulness is the awareness that emerges through paying attention on purpose, in the present moment, and nonjudgementally to the unfolding of experience moment to moment. Mindfulness-based interventions are frequently used in clinical situations and in establishing psychological well-being in a non-clinical sample as psychological techniques. Therefore, many mindfulness measures have been developed for use in clinical settings and for research purposes. Freiburg Mindfulness Inventory (FMI) is a self-report questionnaire that was developed to measure the trait mindfulness. In this study, we aimed to examine the validity, reliability, and factor structure of the FMI in a Turkish sample. METHODS: Participants were mostly college students (113 female, 93 male) and civil servants. Sociodemographic information, the Turkish version of the FMI, Acceptance and Action Questionnaire-II (AAQ-II), Five Facets Mindfulness Questionnaire (FFMQ) – All statistical analyses were performed by using SPSS version 20 and AMOS 23 version. RESULTS: The Cronbach’s alpha coefficient for the scale was 0.823, Guttman’s split-half reliability coefficient was 0.828, and test–retest reliability coefficient was 0.895. A positive and statistically significant correlation was found between the Turkish FMI and FFMQ (r = 0.566, p = .000). We found negative and statistically significant results between FMI and AAQ-II scores (r = −0.519 p = .000). We found strong statistical fit indices that can be acceptable for one-factor solution confirmatory factor analysis. CONCLUSIONS: The Turkish version of the FMI has satisfactory convergent and divergent validity, good internal and test–retest reliability with one-factor structure to use in a Turkish sample. We hope that Turkish form of FMI, which is known to be effective in assessing the mindfulness especially in a population that is familiar with the mindfulness practices, will be a useful alternative instrument for Turkish clinicians and researchers.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"17 1","pages":"472 - 478"},"PeriodicalIF":0.7,"publicationDate":"2019-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89432989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-08-31DOI: 10.1080/24750573.2019.1653134
Meltem Çınar, Pelin Kutlutürk, İ. Ertek, B. Coşar
ABSTRACT OBJECTIVE: Delusional parasitosis (DP), also known as Ekbom’s Syndrome, is a rare, generally monosymptomatic disorder that characterizes with the fixed belief of being infected by parasites without any evidence of medical or microbiological proof. These patients are examined in dermatology and infection clinics with symptoms and signs of pruritus, skin and subcutaneous scars secondary to itching. Primary DP is diagnosed when no etiological factor is detected while secondary DP arises from underlying physical or mental disorder. Formerly, pimozide was the commonly preferred choice of treatment with cases of DP. However, there is growing evidence that second-generation antipsychotics and antidepressants can be used in the treatment of DP. In this study, the usage of aripiprazole in the treatment of DP cases is presented. METHODS: 8 patients with the diagnosis of primary DP were evaluated in terms of demographic data, clinical variables and responses to treatment. A psychiatric diagnosis was made based on a clinical interview performed using Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) SCID-I. The patients were followed for six months. Three patients were female, five patients were male. The average age of the patients was 57.5. Four patients had essential hypertension as comorbidity. The duration of the symptoms ranged from 6 to 48 months with an average of 24.75 months. All of our 8 cases were consulted by the dermatology department. The patients were performed Hamilton Depression Scale (HDS) and Mini-Mental Status Examination (MMSE). Eight patients were treated with aripiprazole 10 or 15 mg/day, and no dose alteration was made. RESULTS: From the patients who were treated with aripiprazole, seven (87.5%) patients had complete remission after three months, eight (100%) patients achieved complete remission after six months. DISCUSSION: The earliest drug choice for patients with DP was pimozide, but because of the extrapyramidal side effects and cardiac side effects like QTc prolongation, second-generation antipsychotics are being investigated for treatment. Various researches are available related to the usage of second-generation antipsychotics like risperidone, olanzapine, paliperidone, ziprasidone, quetiapine, and aripiprazole in the cases with DP. This study shows that aripiprazole can be a successful treatment choice for DP, but further studies are needed for this topic.
{"title":"Aripiprazole as a treatment option for delusional parasitosis: case series of 8 patients","authors":"Meltem Çınar, Pelin Kutlutürk, İ. Ertek, B. Coşar","doi":"10.1080/24750573.2019.1653134","DOIUrl":"https://doi.org/10.1080/24750573.2019.1653134","url":null,"abstract":"ABSTRACT OBJECTIVE: Delusional parasitosis (DP), also known as Ekbom’s Syndrome, is a rare, generally monosymptomatic disorder that characterizes with the fixed belief of being infected by parasites without any evidence of medical or microbiological proof. These patients are examined in dermatology and infection clinics with symptoms and signs of pruritus, skin and subcutaneous scars secondary to itching. Primary DP is diagnosed when no etiological factor is detected while secondary DP arises from underlying physical or mental disorder. Formerly, pimozide was the commonly preferred choice of treatment with cases of DP. However, there is growing evidence that second-generation antipsychotics and antidepressants can be used in the treatment of DP. In this study, the usage of aripiprazole in the treatment of DP cases is presented. METHODS: 8 patients with the diagnosis of primary DP were evaluated in terms of demographic data, clinical variables and responses to treatment. A psychiatric diagnosis was made based on a clinical interview performed using Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) SCID-I. The patients were followed for six months. Three patients were female, five patients were male. The average age of the patients was 57.5. Four patients had essential hypertension as comorbidity. The duration of the symptoms ranged from 6 to 48 months with an average of 24.75 months. All of our 8 cases were consulted by the dermatology department. The patients were performed Hamilton Depression Scale (HDS) and Mini-Mental Status Examination (MMSE). Eight patients were treated with aripiprazole 10 or 15 mg/day, and no dose alteration was made. RESULTS: From the patients who were treated with aripiprazole, seven (87.5%) patients had complete remission after three months, eight (100%) patients achieved complete remission after six months. DISCUSSION: The earliest drug choice for patients with DP was pimozide, but because of the extrapyramidal side effects and cardiac side effects like QTc prolongation, second-generation antipsychotics are being investigated for treatment. Various researches are available related to the usage of second-generation antipsychotics like risperidone, olanzapine, paliperidone, ziprasidone, quetiapine, and aripiprazole in the cases with DP. This study shows that aripiprazole can be a successful treatment choice for DP, but further studies are needed for this topic.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"9 1","pages":"794 - 797"},"PeriodicalIF":0.7,"publicationDate":"2019-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82146366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-08-30DOI: 10.1080/24750573.2019.1645410
E. Akatay, Tuğba Yüksel, Nazan Ekinci, Bilge Didem Tunali, Selin Ayşe İpek Baş, Ö. İ. Doğan, Özalp Ekinci
It is defined as childhood onset or early onset schizophrenia when it starts at the age of 13. In this presentation, a male patient who was diagnosed with schizophrenia at age 10 was discussed. Case presentation: A 10-year-old male patient presented to our outpatient clinic with complaints of nervousness, aggression, introversion, and self-talk, which started about 9 months ago. The parents reported observed disorganized behaviour in the form of self-talk and laughter, nightly fears, repetitive conversations and gestures, trusting people, and wanting to kill them, putting his hand in his mouth and butt, going under the table all the time in class. The patient had aphonia, which started three days before he arrived in our outpatient clinic. No organic pathology was found in the neurological examination and his brain MRI exam was unremarkable. No psychiatric history in the family were reported. Parents reported that he started walking in 15 months, and he started speaking when he was 5–6 years old. In his psychiatric examination, distraction of the patient during the interview, incoherence, the blocks of thought, self-talk and laughter, and disorganized behaviour were remarkable. Patient was diagnosed with schizophrenia and olanzapine treatment was started and he was followed regularly. Our case is important in terms of starting at an early age, quick onset of symptoms, and poor functionality. Due to the facts that the age of our patient was young and his parents were not cooperating in the treatment, these affected the clinical prognosis negatively. Treatment guidelines for earlyonset schizophrenia are based on adult literature and clinical experience, and therefore further studies are needed in the child age group for effective treatment.
{"title":"11th International Congress on Psychopharmacology & 7th International Symposium on Child and Adolescent Psychopharmacology Case Reports Addendum","authors":"E. Akatay, Tuğba Yüksel, Nazan Ekinci, Bilge Didem Tunali, Selin Ayşe İpek Baş, Ö. İ. Doğan, Özalp Ekinci","doi":"10.1080/24750573.2019.1645410","DOIUrl":"https://doi.org/10.1080/24750573.2019.1645410","url":null,"abstract":"It is defined as childhood onset or early onset schizophrenia when it starts at the age of 13. In this presentation, a male patient who was diagnosed with schizophrenia at age 10 was discussed. Case presentation: A 10-year-old male patient presented to our outpatient clinic with complaints of nervousness, aggression, introversion, and self-talk, which started about 9 months ago. The parents reported observed disorganized behaviour in the form of self-talk and laughter, nightly fears, repetitive conversations and gestures, trusting people, and wanting to kill them, putting his hand in his mouth and butt, going under the table all the time in class. The patient had aphonia, which started three days before he arrived in our outpatient clinic. No organic pathology was found in the neurological examination and his brain MRI exam was unremarkable. No psychiatric history in the family were reported. Parents reported that he started walking in 15 months, and he started speaking when he was 5–6 years old. In his psychiatric examination, distraction of the patient during the interview, incoherence, the blocks of thought, self-talk and laughter, and disorganized behaviour were remarkable. Patient was diagnosed with schizophrenia and olanzapine treatment was started and he was followed regularly. Our case is important in terms of starting at an early age, quick onset of symptoms, and poor functionality. Due to the facts that the age of our patient was young and his parents were not cooperating in the treatment, these affected the clinical prognosis negatively. Treatment guidelines for earlyonset schizophrenia are based on adult literature and clinical experience, and therefore further studies are needed in the child age group for effective treatment.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"26 1","pages":"447 - 453"},"PeriodicalIF":0.7,"publicationDate":"2019-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81283053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-08-16DOI: 10.1080/24750573.2019.1653149
Tugba Mutu Pek, E. Yazıcı, Derya Guzel, E. Kose, A. Yazıcı, Atila Erol
ABSTRACT Objective: The aim of this study was to investigate the relationship between oxytocin (OXT), vasopressin (AVP) and atrial natriuretic peptide (ANP) levels and cognitive functions in schzophrenia as well as to compare the findings to those in healthy controls. Method: Patients with chronic schizophrenia and (n=63) healthy controls (n=60) were evaluated with the Rey Auditory Verbal Learning Test (VLT), the Trail Making Test A-B (TMT), the Stroop Test, the Wechsler Memory Scale-Visual Production Subscale (WMS-V) and the Facial Emotion Recognition Tests. Blood samples were analysed by using ELISA. In the data analysis, the percentage distributions of the variables were obtained, the centrality and prevalence measures (mean, standard deviation) were calculated for the continuous variables, and the dependent and independent variables were evaluated using the chi-square test, the Student’s t-test, and the Pearson correlation test. High score variables were determined by principal component analysis. For comparisons between groups; MANOVA applied. Results: Serum OXT, AVP and ANP levels did not differ between the groups. In the healthy control group, subscales of the Stroop, WMS-V and TMT-B tests showed better scores and correlated with levels of OXT (p < .05). In the healthy controls, ANP levels and social cognition had a relationship with response times to happy facial expressions (p < .05). The correlations of OXT, AVP and ANP with the social and cognitive parameters were different between the control group and the schizophrenia group (p < .05). Conclusion: The different correlations in the healthy controls and schizophrenia group suggest deteriorations in the interactions and functions of hormones in patients and highlights the need for new investigations into different neurodegenerative illness samples.
{"title":"The relationship between oxytocin, vasopressin and atrial natriuretic peptide levels and cognitive functions in patients with schizophrenia","authors":"Tugba Mutu Pek, E. Yazıcı, Derya Guzel, E. Kose, A. Yazıcı, Atila Erol","doi":"10.1080/24750573.2019.1653149","DOIUrl":"https://doi.org/10.1080/24750573.2019.1653149","url":null,"abstract":"ABSTRACT Objective: The aim of this study was to investigate the relationship between oxytocin (OXT), vasopressin (AVP) and atrial natriuretic peptide (ANP) levels and cognitive functions in schzophrenia as well as to compare the findings to those in healthy controls. Method: Patients with chronic schizophrenia and (n=63) healthy controls (n=60) were evaluated with the Rey Auditory Verbal Learning Test (VLT), the Trail Making Test A-B (TMT), the Stroop Test, the Wechsler Memory Scale-Visual Production Subscale (WMS-V) and the Facial Emotion Recognition Tests. Blood samples were analysed by using ELISA. In the data analysis, the percentage distributions of the variables were obtained, the centrality and prevalence measures (mean, standard deviation) were calculated for the continuous variables, and the dependent and independent variables were evaluated using the chi-square test, the Student’s t-test, and the Pearson correlation test. High score variables were determined by principal component analysis. For comparisons between groups; MANOVA applied. Results: Serum OXT, AVP and ANP levels did not differ between the groups. In the healthy control group, subscales of the Stroop, WMS-V and TMT-B tests showed better scores and correlated with levels of OXT (p < .05). In the healthy controls, ANP levels and social cognition had a relationship with response times to happy facial expressions (p < .05). The correlations of OXT, AVP and ANP with the social and cognitive parameters were different between the control group and the schizophrenia group (p < .05). Conclusion: The different correlations in the healthy controls and schizophrenia group suggest deteriorations in the interactions and functions of hormones in patients and highlights the need for new investigations into different neurodegenerative illness samples.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"324 1","pages":"798 - 810"},"PeriodicalIF":0.7,"publicationDate":"2019-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78408541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-08-13DOI: 10.1080/24750573.2019.1606883
N. Müller
Selected publications: Müller N and Schwarz MJ. (2007) The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neural Transm (Suppl 72): 269-280. Müller N and Schwarz MJ. (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 1-13. (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo-controlled, add-on pilot study to reboxetine. Molecular Psychiatry 11: 680-684. (2002) Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.
{"title":"11th International Congress on Psychopharmacology & 7th International Symposium on Child and Adolescent Psychopharmacology","authors":"N. Müller","doi":"10.1080/24750573.2019.1606883","DOIUrl":"https://doi.org/10.1080/24750573.2019.1606883","url":null,"abstract":"Selected publications: Müller N and Schwarz MJ. (2007) The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neural Transm (Suppl 72): 269-280. Müller N and Schwarz MJ. (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 1-13. (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo-controlled, add-on pilot study to reboxetine. Molecular Psychiatry 11: 680-684. (2002) Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"26 1","pages":"311 - 446"},"PeriodicalIF":0.7,"publicationDate":"2019-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75515549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：